Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM2 | P31350 | 8/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CTH | P32929 | 1/20 | 0.47 |
| ▸ | RRM1 | P23921 | 1/20 | 0.47 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.47 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30094126 | 1.00 | RRM2 (0.67) | RRM2KDM4EGAAL3MBTL1CTH | |
| SCHEMBL783292 | 1.00 | RRM2 (0.67) | RRM2KDM4EGAAL3MBTL1CTH | |
| SCHEMBL783293 | 1.00 | RRM2 (0.67) | RRM2KDM4EGAAL3MBTL1CTH | |
| SCHEMBL7749775 | 0.84 | RRM2 (0.67) | RRM2KDM4ECTHRRM1RRM2B | |
| SCHEMBL31753656 | 0.84 | RRM2 (0.67) | RRM2KDM4ECTHRRM1RRM2B | |
| SCHEMBL4382591 | 0.84 | RRM2 (0.67) | RRM2KDM4ECTHRRM1RRM2B | |
| SCHEMBL8685653 | 0.77 | MAPT (0.64) | RRM2KDM4EGAA | |
| SCHEMBL6261110 | 0.76 | RRM2 (0.71) | RRM2KDM4ECTH | |
| SCHEMBL6261112 | 0.76 | RRM2 (0.71) | RRM2KDM4ECTH | |
| SCHEMBL534248 | 0.75 | TOP2A (0.68) | RRM2L3MBTL1CTHRRM1RRM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| WO-2026085795-A1 | SILENCED FC REGIONS | PROTEINTECH GROUP, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260056209-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260049127-A1 | METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-19 | — | — | US | disclosed |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | disclosed |
| EP-3972993-A1 | VARIANT CD58 DOMAINS AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| CN-114246953-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3247727-B1 | INHIBITORS OF THE INTERACTION BETWEEN CLEC14A AND MULTIMERIN-2 FOR INHIBITION OF ANGIOGENESIS | CANCER RESEARCH TECH LTD (GB) | 2022-03-23 | — | — | EP | disclosed |
| CN-114177262-A | Application of zucchini in inhibiting gastric mucositis caused by helicobacter pylori infection | 西藏甘露藏药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114173810-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC3, HDAC1, HDAC4 | RRM2 275/4885KDM4E 354/4885GAA 776/4885 |
| US-20260056209-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | CCR8, CCR3, CCR1 | RRM2 1437/4885KDM4E 3338/4885GAA 4728/4885 |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | RRM2 1100/4885KDM4E 2354/4885GAA 1704/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | RRM2 957/4885KDM4E 902/4885GAA 2156/4885 |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | RRM2 1660/4885KDM4E 4105/4885GAA 217/4885 |
| US-20260049127-A1 | METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS | HBG1, PYGB, HBB | RRM2 2817/4885KDM4E 4615/4885GAA 235/4885 |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC7, HDAC5 | RRM2 2452/4885KDM4E 210/4885GAA 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.